CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
|Videos|September 13, 2022
Cate Lockhart Presents on the Uptake of Biosimilars at PBMI 2022
Author(s)Briana Contreras
Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.
Advertisement
Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.
Advertisement
Related to this article
Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.
Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.
Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
One of teledentistry's most valuable applications is triage — helping a patient understand whether a concern can wait for an appointment, requires prompt attention or warrants emergency medical care.
Low birth volume fuels rural healthcare obstetric closures, limiting women’s health access—see which hospitals are most at risk.
In both mice and human cells, a small molecule selectively blocked the activity of MAP4K4, a protein involved in several major biological pathways.
Steering claims away from 340B-eligible pharmacies is one option but also the most disruptive, said Jeff Dunn, Pharm.D., MBA, of NeosRx.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Heather Burrell Ward, M.D., on personalizing TMS in schizophrenia
2
Why consumers still can’t comparison shop for medication
3
Teledentistry is a step in closing the gap in dental care
4
FDA approves Lilly’s Onswik, the second once-weekly insulin
5